Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia

Clozapine (CLZ), the sole antipsychotic with superior efficacy for ultra-treatment resistant schizophrenia (TRS), is limited by adverse effects, including metabolic dysregulation. Clozapine’s main metabolite, N-desmethylclozapine (NDMC), has potent 5-HT2C antagonist properties which may explain this...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa-Dookhan, Kenya A., Rajji, Tarek K., Tran, Veronica N., Bowden, Sylvie, Mueller, Daniel J., Remington, Gary J., Agarwal, Sri Mahavir, Hahn, Margaret K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820218/
https://www.ncbi.nlm.nih.gov/pubmed/33479273
http://dx.doi.org/10.1038/s41598-021-81493-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820218/
https://www.ncbi.nlm.nih.gov/pubmed/33479273
http://dx.doi.org/10.1038/s41598-021-81493-0

Ejemplares similares